NeuroSense details Health Canada talks on ALS drug

NeuroSense Therapeutics reports a regulatory milestone for its ALS drug candidate PrimeC.

Rhea-AI Filing Summary

NeuroSense Therapeutics reports a regulatory milestone for its ALS drug candidate PrimeC. The company recently held a constructive meeting with Health Canada to discuss potential regulatory pathways supporting a New Drug Submission (NDS) for treating amyotrophic lateral sclerosis.

NeuroSense presented additional clinical, biomarker, and long-term outcome data as previously requested by Health Canada, and outlined its proposed NDS strategy. The company expects an official response from Health Canada in the third quarter this year and plans to provide further updates on the Canadian regulatory process.

Insights

Biopharma regulatory analyst

NeuroSense advances Canadian regulatory dialogue on ALS drug PrimeC.

NeuroSense Therapeutics engaged Health Canada in a constructive meeting about regulatory pathways for PrimeC in amyotrophic lateral sclerosis. The discussion centered on a potential New Drug Submission, backed by additional clinical, biomarker, and long-term outcome data requested by the regulator.

This marks movement from data generation toward formal registration planning in Canada, but no filing or approval has occurred yet. The next key step is Health Canada’s official response, currently expected in the third quarter this year, which will clarify subsequent regulatory requirements.

Key Figures

Expected Health Canada response timing: third quarter this year Meeting date disclosure: June 8, 2026

2 metrics

Expected Health Canada response timing third quarter this year Timing for official response on PrimeC regulatory path in Canada

Meeting date disclosure June 8, 2026 Date NeuroSense announced it had recently met with Health Canada

Key Terms

New Drug Submission (NDS), amyotrophic lateral sclerosis (ALS), biomarker, long-term outcome data, +1 more

5 terms

New Drug Submission (NDS) regulatory

"in order to support a New Drug Submission (NDS) the Company presented additional data"

A new drug submission (NDS) is a formal application filed with a health regulator asking for permission to market a new medicine, and it includes the data, safety and effectiveness evidence, and manufacturing details needed for review. For investors, the NDS outcome and its review timeline drive whether and when a drug can generate revenue, so acceptance, delay, or rejection materially affects a drugmaker’s future sales prospects and risk—like a building permit deciding if a project can move forward.

amyotrophic lateral sclerosis (ALS) medical

"potential regulatory pathways for PrimeC for treating amyotrophic lateral sclerosis (ALS)"

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that damages nerve cells responsible for controlling voluntary muscles, leading to muscle weakness, loss of movement, and eventually paralysis. It matters to investors because health-related research, treatments, and biotech companies working on ALS can influence stock markets and create opportunities or risks within the healthcare sector.

biomarker medical

"the clinical, biomarker, and long-term outcome data supporting a potential NDS filing"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

long-term outcome data medical

"the clinical, biomarker, and long-term outcome data supporting a potential NDS filing"

Report of Foreign Private Issuer regulatory

"FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A report of a foreign private issuer is a formal filing that a non‑U.S. company makes to U.S. regulators to share important business, financial, or governance information with American investors. Think of it as a regular update or press packet that keeps investors informed about events that could change a company’s value—like earnings, management changes, contracts, or regulatory developments—so investors can make timely, informed decisions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NeuroSense Therapeutics (NRSN) announce in its June 2026 Form 6-K?

NeuroSense announced it held a constructive meeting with Health Canada about regulatory pathways for PrimeC in ALS. The discussion focused on a potential New Drug Submission, supported by additional clinical, biomarker, and long-term outcome data the company provided at the regulator’s request.

What is the focus of NeuroSense Therapeutics’ discussions with Health Canada on PrimeC?

The discussions focus on NeuroSense’s proposed New Drug Submission strategy for PrimeC to treat ALS in Canada. Health Canada reviewed additional clinical, biomarker, and long-term outcome data to assess how these results support a potential NDS filing and future regulatory steps.

What additional data did NeuroSense Therapeutics (NRSN) present to Health Canada?

NeuroSense presented additional clinical data, biomarker results, and long-term outcome data for PrimeC, as previously requested by Health Canada. This information is intended to support a potential New Drug Submission for treating ALS and to inform the regulator’s evaluation of the program’s evidence base.

When does NeuroSense Therapeutics expect a response from Health Canada on PrimeC?

NeuroSense currently expects an official response from Health Canada in the third quarter this year. That response will address the regulatory process in Canada for a potential New Drug Submission for PrimeC, and the company plans to provide further updates after receiving it.

Does NeuroSense’s Form 6-K report an approved New Drug Submission for PrimeC in Canada?

No, the report describes a constructive meeting with Health Canada and discussion of a potential New Drug Submission for PrimeC. NeuroSense is awaiting an official response from the regulator, expected in the third quarter this year, before any NDS filing or approval can be confirmed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 09:05 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of June 2026

Commission File Number: 001-41084

NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)

NeuroSense Therapeutics Ltd.

11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9-7996183
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Explanatory Note

On June 8, 2026, NeuroSense Therapeutics Ltd. (the “Company”) announced that it recently held a constructive meeting with Health Canada regarding potential regulatory pathways for PrimeC for treating amyotrophic lateral sclerosis (ALS).

As previously requested by Health Canada, in order to support a New Drug Submission (NDS) the Company presented additional data, and the discussion focused on the Company's proposed NDS strategy and the clinical, biomarker, and long-term outcome data supporting a potential NDS filing.

The Company will provide additional updates regarding the regulatory process in Canada once an official response from Health Canada is received, currently expected in the third quarter this year.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NeuroSense Therapeutics Ltd.
Date: June 8, 2026	By:	/s/ Alon Ben-Noon
		Alon Ben-Noon
		Chief Executive Officer

2